



Contact: Dr. Anthony Ferrante
Location: 20 New England Business Center
 Andover, MA 01810
Email: ferrante@psicorp.com
Tel: 978-689-0003

Physical Sciences Inc.



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
 National Institutes of Health



National Institutes of Health Commercialization Assistance Program
 (NIH-CAP)

Company Overview

Industry Sector: High Content Instrumentation for Drug Discovery

Company Overview: An employee owned company founded in 1973 focused on providing contract R&D services to government and commercial customers. Expertise encompassing biology, optics, electronics, materials, mechanics and chemistry, photonics and optoelectronics, electro-mechanics, electrochemistry, and materials.

Target Market(s): Drug Discovery, Predictive Toxicology

Key Value Drivers


Technology*: Use Optical Coherence Tomography (OCT) and optical Doppler Near infrared for deep tissue penetration. Structural Information from OCT Doppler measurement of temporal velocity. Provides mean flow across vessel over time. Movement of blood provides contrast

Competitive Advantage:

Moderate-throughput / high content,
 Low cost vertebrate animal model,
 Small quantities of drug required for testing

Plan & Strategy: seeking a strategic partner

*Technology funded by the NHLBI and being commercialized under the NIH-CAP



Management

Leadership:

Anthony Ferrante, PhD, Group Leader, Biological Sciences
 Mark Druy, PhD, Technology Transition Manager
 E. Jennings Taylor, PhD, Intellectual Property Manager
 B. David Green, PhD, President & CEO

Product Development

PSI is currently developing an advanced prototype for near infrared optical imaging assay that will detect changes in cardiac output and heart rhythm caused by drug candidates

Custom Instrument Sales: 2010
 Product Launch: 2011

PSI SideView™ Microplates available at www.sideviewmicroplate.com